310 related articles for article (PubMed ID: 18184661)
1. Bone morphogenetic proteins signal through the transforming growth factor-beta type III receptor.
Kirkbride KC; Townsend TA; Bruinsma MW; Barnett JV; Blobe GC
J Biol Chem; 2008 Mar; 283(12):7628-37. PubMed ID: 18184661
[TBL] [Abstract][Full Text] [Related]
2. The balance of cell surface and soluble type III TGF-β receptor regulates BMP signaling in normal and cancerous mammary epithelial cells.
Gatza CE; Elderbroom JL; Oh SY; Starr MD; Nixon AB; Blobe GC
Neoplasia; 2014 Jun; 16(6):489-500. PubMed ID: 25077702
[TBL] [Abstract][Full Text] [Related]
3. Endoglin differentially modulates antagonistic transforming growth factor-beta1 and BMP-7 signaling.
Scherner O; Meurer SK; Tihaa L; Gressner AM; Weiskirchen R
J Biol Chem; 2007 May; 282(19):13934-43. PubMed ID: 17376778
[TBL] [Abstract][Full Text] [Related]
4. The transforming growth factor-beta type III receptor mediates distinct subcellular trafficking and downstream signaling of activin-like kinase (ALK)3 and ALK6 receptors.
Lee NY; Kirkbride KC; Sheu RD; Blobe GC
Mol Biol Cell; 2009 Oct; 20(20):4362-70. PubMed ID: 19726563
[TBL] [Abstract][Full Text] [Related]
5. ALK1 regulates the internalization of endoglin and the type III TGF-β receptor.
Tazat K; Pomeraniec-Abudy L; Hector-Greene M; Szilágyi SS; Sharma S; Cai EM; Corona AL; Ehrlich M; Blobe GC; Henis YI
Mol Biol Cell; 2021 Apr; 32(7):605-621. PubMed ID: 33566682
[TBL] [Abstract][Full Text] [Related]
6. Ligand binding and functional properties of betaglycan, a co-receptor of the transforming growth factor-beta superfamily. Specialized binding regions for transforming growth factor-beta and inhibin A.
Esparza-Lopez J; Montiel JL; Vilchis-Landeros MM; Okadome T; Miyazono K; López-Casillas F
J Biol Chem; 2001 May; 276(18):14588-96. PubMed ID: 11278442
[TBL] [Abstract][Full Text] [Related]
7. Bone morphogenetic proteins induce pancreatic cancer cell invasiveness through a Smad1-dependent mechanism that involves matrix metalloproteinase-2.
Gordon KJ; Kirkbride KC; How T; Blobe GC
Carcinogenesis; 2009 Feb; 30(2):238-48. PubMed ID: 19056927
[TBL] [Abstract][Full Text] [Related]
8. Inhibin is an antagonist of bone morphogenetic protein signaling.
Wiater E; Vale W
J Biol Chem; 2003 Mar; 278(10):7934-41. PubMed ID: 12493742
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of type III TGF-β receptor aggravates lung fibrotic process.
Ahn JY; Park S; Yun YS; Song JY
Biomed Pharmacother; 2010 Sep; 64(7):472-6. PubMed ID: 20359848
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor β inhibits bone morphogenetic protein-induced transcription through novel phosphorylated Smad1/5-Smad3 complexes.
Grönroos E; Kingston IJ; Ramachandran A; Randall RA; Vizán P; Hill CS
Mol Cell Biol; 2012 Jul; 32(14):2904-16. PubMed ID: 22615489
[TBL] [Abstract][Full Text] [Related]
11. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily.
Barbara NP; Wrana JL; Letarte M
J Biol Chem; 1999 Jan; 274(2):584-94. PubMed ID: 9872992
[TBL] [Abstract][Full Text] [Related]
12. The type III TGF-beta receptor signals through both Smad3 and the p38 MAP kinase pathways to contribute to inhibition of cell proliferation.
You HJ; Bruinsma MW; How T; Ostrander JH; Blobe GC
Carcinogenesis; 2007 Dec; 28(12):2491-500. PubMed ID: 17768179
[TBL] [Abstract][Full Text] [Related]
13. Type III TGF-β receptor enhances colon cancer cell migration and anchorage-independent growth.
Gatza CE; Holtzhausen A; Kirkbride KC; Morton A; Gatza ML; Datto MB; Blobe GC
Neoplasia; 2011 Aug; 13(8):758-70. PubMed ID: 21847367
[TBL] [Abstract][Full Text] [Related]
14. Altering the Proteoglycan State of Transforming Growth Factor β Type III Receptor (TβRIII)/Betaglycan Modulates Canonical Wnt/β-Catenin Signaling.
Jenkins LM; Singh P; Varadaraj A; Lee NY; Shah S; Flores HV; O'Connell K; Mythreye K
J Biol Chem; 2016 Dec; 291(49):25716-25728. PubMed ID: 27784788
[TBL] [Abstract][Full Text] [Related]
15. Growth differentiation factor-9 signaling is mediated by the type I receptor, activin receptor-like kinase 5.
Mazerbourg S; Klein C; Roh J; Kaivo-Oja N; Mottershead DG; Korchynskyi O; Ritvos O; Hsueh AJ
Mol Endocrinol; 2004 Mar; 18(3):653-65. PubMed ID: 14684852
[TBL] [Abstract][Full Text] [Related]
16. TβRIII independently binds type I and type II TGF-β receptors to inhibit TGF-β signaling.
Tazat K; Hector-Greene M; Blobe GC; Henis YI
Mol Biol Cell; 2015 Oct; 26(19):3535-45. PubMed ID: 26269580
[TBL] [Abstract][Full Text] [Related]
17. A tumor-promoting role for soluble TβRIII in glioblastoma.
Burghardt I; Schroeder JJ; Weiss T; Gramatzki D; Weller M
Mol Cell Biochem; 2021 Aug; 476(8):2963-2973. PubMed ID: 33772427
[TBL] [Abstract][Full Text] [Related]
18. Activation of the bone morphogenetic protein signaling pathway induces inhibin beta(B)-subunit mRNA and secreted inhibin B levels in cultured human granulosa-luteal cells.
Jaatinen R; Bondestam J; Raivio T; Hildén K; Dunkel L; Groome N; Ritvos O
J Clin Endocrinol Metab; 2002 Mar; 87(3):1254-61. PubMed ID: 11889196
[TBL] [Abstract][Full Text] [Related]
19. The type III transforming growth factor-beta receptor negatively regulates nuclear factor kappa B signaling through its interaction with beta-arrestin2.
You HJ; How T; Blobe GC
Carcinogenesis; 2009 Aug; 30(8):1281-7. PubMed ID: 19325136
[TBL] [Abstract][Full Text] [Related]
20. Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression.
Gordon KJ; Dong M; Chislock EM; Fields TA; Blobe GC
Carcinogenesis; 2008 Feb; 29(2):252-62. PubMed ID: 17999987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
